Shanghai Henlius Biotech, Inc. (2696)

Overview

Shanghai Henlius Biotech, Inc. is a leading biopharmaceutical company focused on the development of innovative biologic medicines, primarily serving the fields of oncology, autoimmune diseases, and ophthalmic diseases. Founded in 2010, and based in Shanghai, China, Henlius Biotech has positioned itself as a prominent player in the biotech industry, offering a range of therapeutic solutions to patients across Mainland China, Europe, the rest of the Asia Pacific, and internationally. The company is recognized for its strategic collaborations, notably with HanchorBio Inc., to pioneer cancer immunotherapies designed to combat tumors resistant to anti-PD-1/L1. A subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Henlius continues to expand its global footprint by leveraging cutting-edge research and development to address unmet medical needs.

Products and Services

• HANLIKANG (rituximab injection): Utilized in the treatment of non-hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis, offering patients therapeutic options for managing these conditions.
• HANQUYOU (trastuzumab injection): Aimed at treating breast and metastatic gastric cancer, highlighting Henlius Biotech's commitment to combating prevalent cancer types.
• HANDAYUAN (adalimumab injection): Addresses rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis, thereby providing relief to patients suffering from autoimmune conditions.
• HANBEITAI (bevacizumab injection): Focuses on metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer, offering options to manage these challenging cancers.
• HANSIZHUANG (serplulimab injection): Targets microsatellite instability-high solid tumors, representing Henlius Biotech's innovative approach to treating complex cancers.
• Development of Serplulimab continues, aimed at various cancer types including squamous non-small cell lung cancer and extensive small-cell lung cancer, showcasing Henlius Biotech's ongoing mission to broaden its oncology portfolio.
• HLX04-O: An anti-VEGF monoclonal antibody injection for wet age-related macular degeneration, demonstrating Henlius Biotech's expansion into ophthalmic diseases.
• Henlius Biotech's solid tumor treatments, including HLX22 for breast and metastatic gastric cancer, and various other HLX compounds (HLX07, HLX41, HLX35, HLX208, HLX53, HLX301, and HLX20), highlight their diversified and extensive research in cancer therapeutics.
• HLX11 for breast cancer, HLX05 (a cetuximab injection) for mCRC and HNSCC, and HLX14 for osteoporosis reflect the company's dedication to addressing a broad spectrum of diseases with high unmet medical needs.
• The development of HLX26 for solid tumor and lymphoma, HLX13 for melanoma, HCC, renal cell carcinoma, and mCRC, and HLX15 for multiple myeloma, underscores Henlius Biotech's ongoing commitment to innovating in the field of cancer treatment and beyond.